Pharsight to Present at DIA Cardiac Safety Conference on Decemb...( Dr. Timothy Carrothers Will Present ...),Health

Dr. Timothy Carrothers Will Present Case Example on the Value of Modeling

and Simulation to Assess Potential for QTc Prolongation

MOUNTAIN VIEW, Calif., Nov. 28 /PRNewswire-FirstCall/ -- Pharsight Corporation (Nasdaq: PHST), a leading provider of software, strategic consulting, and regulatory services for optimizing clinical drug development, today announced that Timothy Carrothers, Sc.D., senior scientist, Strategic Consulting Services, has been invited to speak to members of the pharmaceutical and biotechnology industries attending the 2nd Annual Drug Information Association (DIA) Cardiac Safety Conference, to be held in Prague, Czech Republic at the Dorint Praha Don Giovanni Hotel from December 3-4, 2007.

Dr. Carrothers will present a case study on the value of model-based approaches to assess drug effects on QTc prolongation and develop future clinical studies required for new drug approval. Dr. Carrothers' presentation, "Concordance Between the Exposure-QTc Response Relationship in the Pooled Phase 1 Data vs. Thorough QTc Study", is part of a dedicated conference session led by pharmaceutical sponsors and regulators on modeling the relationship between plasma concentration of a drug and its effect on QTc prolongation as an indicator of cardiac arrhythmic risk. The session speakers will present applied research on concentration-QTc modeling and discuss perspectives for its contribution to decisions on the development, regulatory approval and labeling of new drugs. A panel discussion will also provide a forum for scientific discussion and collaborative exchange on exposure-QTc response modeling. Additional information can be found at http://www.d
'/>"/>